Inovio's VOCERYQ wins accelerated FDA approval for RRP, company reports Q3 2026 results
FDA cleared the first DNA medicine on October 30, 2026, as Inovio plans a 2027 launch and reports cash runway into late Q4 2027.
Inovio Pharmaceuticals said on November 10, 2026 that the FDA granted accelerated approval on October 30, 2026 to VOCERYQ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) to reduce the frequency of surgery in adults with Recurrent Respiratory Papillomatosis.1 The company said the approval rested on data showing patients achieved a complete response, meaning no surgery was needed in the 12 months following treatment, within the efficacy population studied.1 VOCERYQ was approved for use alongside CELLECTRA 5PSP, Inovio's proprietary delivery device.1
The approval drew on Inovio's RRP-001 study, which evaluated 32 adult RRP patients across multiple sites and found the treatment well tolerated.1 Because this is an accelerated approval, Inovio expects to run a confirmatory study and plans to submit a draft protocol to FDA by the end of 2026, aiming to align on a final protocol by mid-2027.1 The company also said it plans to submit an application for conditional marketing authorization for VOCERYQ in Europe before the end of 2026.1
On commercialization, Inovio expects VOCERYQ to be available to order and ship about 60 days after approval, with full field deployment targeted for the first quarter of 2027, and says current inventory and capacity should support at least the first year of launch through 2027.1 Inovio has engaged Syneos Health to help recruit and deploy its medical and commercial field teams.1
On the pipeline, Inovio presented nonclinical data on its next-generation DNA-Encoded Protein programs at the Soft Bones Third International Meeting on Hypophosphatasia in November 2026,1 and said it is continuing discussions with potential partners to advance that platform in rare diseases including Hemophilia A, Fabry Disease and HPP.1
Financially, cash, cash equivalents and short-term investments stood at $48.4 million as of September 30, 2026, excluding roughly $80.5 million in net proceeds from a November 2026 public offering.1 Inovio said this funding, plus $10.9 million from warrant exercises after quarter-end, should support operations into late fourth quarter 2027, past the VOCERYQ launch, though the estimate excludes future product revenue or additional capital raises.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.